Protalix BioTherapeutics - 49 Year Dividend History | PLX

Historical dividend payout and yield for Protalix BioTherapeutics (PLX) since 1971. The current TTM dividend payout for Protalix BioTherapeutics (PLX) as of May 28, 2020 is $0.00. The current dividend yield for Protalix BioTherapeutics as of May 28, 2020 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.111B $0.055B
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Stock Name Country Market Cap PE Ratio